Inhibiting asparagine endopeptidase extended mouse life by four months

Researchers began treating mice at 18 months of age, equivalent to roughly 50 years in humans, and observed a four-month increase in median survival, rising from 24 to 28 months. This outcome aligns with results from late-life rapamycin treatment in mice.

Read the original →